| Patient Safety |
0 |
0.48 |
| Psychotropic Drugs |
0 |
0.98 |
| Lipids Management |
0 |
0.37 |
| Adverse Effects |
0 |
0.97 |
| Cannabinoids |
0 |
0.99 |
| Connecticut |
0 |
0.36 |
| Child |
0 |
0.24 |
| Endocannabinoids |
0 |
0.95 |
| Fatigue |
0 |
0.24 |
| HIV Infection |
0 |
0.24 |
| Tic Disorder |
0 |
0.96 |
| Xerostomia |
0 |
0.17 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.16 |
| Anxiety Disorder |
0 |
0.16 |
| Dentistry and Oral Health |
0 |
0.16 |
| Obsessive-Compulsive Disorder |
0 |
0.16 |
| Antipsychotics |
0 |
0.12 |
| Anxiety |
0 |
0.12 |
| Benzodiazepines |
0 |
0.12 |
| Biomarker |
0 |
0.12 |
| Board Certification |
0 |
0.12 |
| Clinical Guidelines |
0 |
0.12 |
| Clinical Research |
0 |
0.85 |
| Dizziness |
0 |
0.12 |
| Grant |
0 |
0.12 |
| Mouth |
0 |
0.12 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.12 |
| Receptors |
0 |
0.12 |
| Tourette Syndrome |
0 |
1 |